ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Haiyan Xu
Matched on ORCID iD 0000-0002-7287-9048; OpenAlex author ID A5012931311. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 3
2025: 1 paper · 2026: 1 paper
Papers 2
- A Dual-Action CXCR4-Targeted Peptide-Drug Conjugate Engineered to Enhance Antitumor Efficacy and Mitigate Myelosuppression in Pancreatic Cancer. Last author DOI 10.1021/acs.molpharmaceut.6c00292↗
- Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress via enhancing T cell responses and sensitizing cells to gemcitabine. Last author DOI 10.1039/d5md00488h↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ke Zhu · 2 shared papers, 2025–2026 · strength 0.50
- Paper A Dual-Action CXCR4-Targeted Peptide-Drug Conjugate Engineered to Enhance Antitumor Efficacy and Mitigate Myelosuppress… DOI 10.1021/acs.molpharmaceut.6c00292↗
- Paper Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress via enhancing T cell responses… DOI 10.1039/d5md00488h↗
- Chen Wang · 1 shared paper, 2025 · strength 0.22
- Xin Huang · 1 shared paper, 2025 · strength 0.22
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.